Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enovis Corporation (NYSE: ENOV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Enovis describes itself as an innovation-driven medical technology growth company with two primary segments, Prevention & Recovery (P&R) and Reconstructive (Recon), and its filings offer detailed insight into how this orthopedic-focused business reports its financial condition, capital structure and governance matters.
Investors can review Form 8-K filings where Enovis reports material events, such as quarterly earnings releases, changes in senior leadership roles, amendments to its credit agreement and other significant corporate developments. For example, recent 8-Ks have covered second- and third-quarter financial results, a retirement transition for a senior human resources executive, and an amendment to the company’s credit agreement that adjusts maturity dates, leverage ratio thresholds and borrowing terms.
Beyond current reports, Enovis’ annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via EDGAR) typically contain segment information for Prevention & Recovery and Reconstructive, discussions of non-GAAP measures such as adjusted EBITDA and adjusted net income, and risk factor disclosures that may reference acquisitions and integration, including the acquisition of Lima. These filings help explain how the company evaluates its performance and manages its medical technology portfolio.
Stock Titan enhances access to Enovis filings by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points in plain language. Users can quickly understand what a new 8-K, 10-Q or 10-K means for Enovis’ operations, capital structure or governance without reading every page. The platform also makes it easier to track items such as credit agreement amendments and other direct financial obligations that Enovis reports under the SEC’s requirements.
Enovis CORP executive Laura Lee Singleton, SVP and Chief HR Officer, filed an initial ownership report. She directly holds 15,552 shares of common stock and an employee stock option covering 1,091 underlying shares at an exercise price of $57.62 per share, expiring on February 27, 2030. The filing also notes unvested restricted stock units and that the option grant vested in three equal installments in 2024, 2025 and 2026.
Enovis Corporation is holding a virtual 2026 annual stockholder meeting on May 19, 2026, where investors will vote on electing ten directors, ratifying Ernst & Young as auditor, an advisory say‑on‑pay vote and an amendment to the 2020 Omnibus Incentive Plan.
For 2025, Enovis reports adjusted earnings per share of $2.24 and adjusted EBITDA of $401.8 million. Annual bonuses for named executives were funded at a company performance factor of 92.2% of target, reflecting net sales and adjusted EBITDA outcomes below internal goals. Long‑term incentives are split between time‑based RSUs and PRSUs tied to relative total shareholder return with a three‑year performance period and a cap at target if absolute TSR is negative.
The proxy highlights a largely independent, MedTech‑experienced board, mandatory director retirement at age 75, robust stock ownership guidelines, a clawback policy, and restrictions on hedging and pledging. In the 2025 advisory vote, approximately 98% of votes cast supported executive pay, which the compensation committee viewed as validation of its pay‑for‑performance framework.
Enovis CORP director Christine Ortiz received a stock grant that increased her direct ownership. On March 31, 2026, she was granted 770 shares of Enovis common stock at a stated price of $0.00 per share, reflecting a compensation-related award rather than an open-market purchase.
After this grant, Ortiz directly holds 15,665 shares of Enovis common stock. The filing shows no accompanying sales or derivative exercises, so this transaction represents a small, routine increase in her equity stake through non-derivative stock compensation.
Enovis Corp received an amended Schedule 13G/A from The Vanguard Group reporting 0 shares beneficially owned, representing 0% of Common Stock as stated in the filing. The amendment explains an internal realignment effective January 12, 2026, under which certain Vanguard subsidiaries report holdings separately.
The filing lists the filer address and certifies no sole or shared voting or dispositive power over Enovis shares. The report is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Enovis Corp’s Chief Administrative Officer, Oliver Engert, made an open-market purchase of company stock. On March 13, 2026, he bought 1,000 shares of Enovis common stock at $23.74 per share. After this transaction, he directly owns 48,640 shares of Enovis common stock.
This was a straightforward open-market buy, increasing his direct equity stake by a relatively small amount compared with his existing holdings.
Enovis CORP Chief Administrative Officer Oliver Engert bought 1,000 shares of common stock in an open-market purchase at a weighted average price of $23.93 per share. This increases his directly owned stake to 47,640 common shares.
The filing notes the purchase was executed through multiple trades within a price range from $23.75 to $24.10 per share. The transaction represents a relatively small addition compared with his total reported holdings, suggesting a routine increase in personal investment exposure to the company.
Enovis Corp’s principal accounting officer John Kleckner received an equity grant of 14,925 shares of common stock on March 9, 2026. The shares were awarded at no cost as restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.
On March 7, 2026, 586 shares were withheld at $24.51 per share to cover tax obligations tied to a restricted stock unit net settlement, which the company notes is not a sale by Kleckner. Following these transactions, he directly holds 25,884 common shares.
Enovis Corp executive Terry D. Ross, Group President, P&R, received a grant of 36,247 shares of common stock in the form of restricted stock units. These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date.
On a related date, 2,376 shares were withheld by the company at $24.5100 per share to cover tax withholding and remittance obligations tied to the net settlement of RSUs; this did not represent an open-market sale. After these transactions, Ross directly holds 68,477 shares of Enovis common stock.
Enovis senior vice president and chief HR officer Patricia A. Lang received a grant of 25,586 restricted stock units of common stock on March 9, 2026 at no cash cost. The award vests in three equal annual installments beginning on the first anniversary of the grant date.
On March 7, 2026, 2,969 shares were withheld at $24.51 per share to cover tax obligations from restricted stock unit settlement, which the company states does not represent a sale by Lang. Following these transactions, she directly holds 75,703 shares of Enovis common stock.
Enovis CORP Group President, Recon Louis Vogt received an equity award and had shares withheld for taxes. On March 9, 2026, he acquired 36,247 shares of common stock at $0.00 per share as a grant of restricted stock units, bringing his direct holdings to 68,875 shares. On March 7, 2026, 1,980 shares were disposed of at $24.51 per share to cover tax withholding obligations connected to a net settlement of restricted stock units, leaving 32,628 shares following that tax event. A footnote clarifies the 1,980-share disposition was solely to satisfy tax withholding and remittance requirements and does not represent a sale by Vogt. Another footnote states the new restricted stock units vest in three equal annual installments beginning on the first anniversary of the grant date.